CXCR1/2 Inhibitor SX-682

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, University of Washington, Roswell Park Cancer Institute

Conditions

Advanced Lung Non-Small Cell CarcinomaMetastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Rectal AdenocarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Multiple MyelomaRefractory Multiple Myeloma

Phase 1

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Active, not recruitingNCT04599140

M.D. Anderson Cancer CenterMetastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma +18

Start: 2020-10-14End: 2026-07-31Updated: 2026-01-22

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06622005

Roswell Park Cancer InstituteRecurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2025-04-10End: 2030-04-10Target: 15Updated: 2025-04-16

Phase 2

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

RecruitingNCT05570825

University of WashingtonMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 +1

Start: 2023-04-06End: 2028-07-01Target: 30Updated: 2025-12-04

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Not yet recruitingNCT07322341

University of WashingtonAdvanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma +2

Start: 2026-06-01End: 2031-11-01Target: 32Updated: 2026-03-13

Related Papers

Abstract CT118: A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractory<i>RAS-</i>mutated microsatellite stable (MSS) colorectal cancer

Cancer Research2023-04-143 citations

STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory <i>RAS-</i>mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2022-06-0110 citations